Evogene Debt-to-Equity Ratio Growth & History (EVGN)
Evogene's debt-to-equity ratio was 0.09 for fiscal 2023.
View full Evogene company overviewEvogene annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | 0.09 | 0.03 | +45.21% |
| 2022 | 2022-12-31 | 0.07 | 0.02 | +30.70% |
| 2021 | 2021-12-31 | 0.05 | −0.00 | −6.13% |
| 2020 | 2020-12-31 | 0.05 | −0.01 | −10.56% |
| 2019 | 2019-12-31 | 0.06 | −0.01 | −9.25% |
| 2018 | 2018-12-31 | 0.07 | — | — |
Evogene quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | 2.21 | — | — |
| Q2 2024 | 2024-06-30 | 0.26 | 0.16 | +155.14% |
| Q4 2023 | 2023-12-31 | 0.09 | 0.03 | +45.21% |
| Q2 2023 | 2023-06-30 | 0.10 | 0.05 | +80.33% |
| Q4 2022 | 2022-12-31 | 0.07 | 0.02 | +30.70% |
| Q2 2022 | 2022-06-30 | 0.06 | 0.02 | +59.68% |
| Q4 2021 | 2021-12-31 | 0.05 | −0.00 | −6.13% |
| Q2 2021 | 2021-06-30 | 0.04 | −0.03 | −45.36% |
| Q4 2020 | 2020-12-31 | 0.05 | −0.01 | −10.56% |
| Q2 2020 | 2020-06-30 | 0.07 | — | — |
| Q4 2019 | 2019-12-31 | 0.06 | −0.01 | −9.25% |
| Q4 2018 | 2018-12-31 | 0.07 | — | — |
Evogene debt-to-equity ratio trends
Over the last five fiscal years, Evogene's debt-to-equity ratio increased from 0.07 to 0.09, a change of 0.03. The latest reported quarter, Q3 2025, shows 2.21.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evogene source filings ↗